A61P 33/00
Antiparasitic agents
A61P33/00 (Antiparasitic agents) appears on 8,748 US grants and 12,191 published applications in this corpus.
Search patents in A61P- Granted patents
- 8,748
- Published applications
- 12,191
- Assignees
- 3,924
- Inventors
- 20,333
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 13 | 0 |
| 1977 | 14 | 0 |
| 1978 | 15 | 0 |
| 1979 | 23 | 0 |
| 1980 | 19 | 0 |
| 1981 | 40 | 0 |
| 1982 | 34 | 0 |
| 1983 | 22 | 0 |
| 1984 | 23 | 0 |
| 1985 | 16 | 0 |
| 1986 | 17 | 0 |
| 1987 | 27 | 0 |
| 1988 | 22 | 0 |
| 1989 | 51 | 0 |
| 1990 | 59 | 0 |
| 1991 | 40 | 0 |
| 1992 | 50 | 0 |
| 1993 | 29 | 0 |
| 1994 | 30 | 0 |
| 1995 | 49 | 0 |
| 1996 | 55 | 0 |
| 1997 | 106 | 0 |
| 1998 | 118 | 0 |
| 1999 | 122 | 0 |
| 2000 | 128 | 0 |
| 2001 | 151 | 55 |
| 2002 | 183 | 236 |
| 2003 | 203 | 457 |
| 2004 | 135 | 574 |
| 2005 | 162 | 537 |
| 2006 | 212 | 513 |
| 2007 | 197 | 489 |
| 2008 | 232 | 574 |
| 2009 | 252 | 634 |
| 2010 | 388 | 899 |
| 2011 | 371 | 816 |
| 2012 | 515 | 824 |
| 2013 | 534 | 561 |
| 2014 | 586 | 631 |
| 2015 | 523 | 577 |
| 2016 | 475 | 563 |
| 2017 | 458 | 511 |
| 2018 | 360 | 456 |
| 2019 | 337 | 467 |
| 2020 | 327 | 387 |
| 2021 | 264 | 320 |
| 2022 | 199 | 331 |
| 2023 | 166 | 271 |
| 2024 | 164 | 219 |
| 2025 | 155 | 186 |
| 2026 | 77 | 103 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chagas disease vaccine antigens with improved stability and decreased aggregation29 Sep 2026US 12,746,280 B2Baylor College of Medicine
- Viral vector therapy22 Sep 2026US 12,741,036 B2Apellis Pharmaceuticals, Inc.
- Permethrin for use in the treatment of Demodex species infestation1 Sep 2026US 12,721,829 B2Tg Pharma Spolka Z Ograniczona Odpowiedzialnoscia
- Anticoccidial composition comprising violacein, and use thereof1 Sep 2026US 12,721,835 B2Cj Cheiljedang Corporation
- Immune priming to accelerate/enhance immune response through administration of natural immune modulator1 Sep 2026US 12,721,889 B2ZIVO Bioscience, Inc.
- Anthelmintic aza-benzothiophene and aza-benzofuran compounds8 Oct 2026US 2026/0308170 A1Boehringer Ingelheim Vetmedica GmbH
- Crispr-cas genome engineering via a modular aav delivery system8 Oct 2026US 2026/0308630 A1The Regents of the University of California
- Biologically compatible, biofilm disrupting composition and methods1 Oct 2026US 2026/0294861 A1
- Long-term prevention and/or treatment of a disease by slo-1 inhibitors1 Oct 2026US 2026/0294890 A1
- Testosterone and difluoromethylornithine combination therapy for prostate cancer24 Sep 2026US 2026/0284076 A1The Johns Hopkins University
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Medical device intended to come into contact with a patient's tissue and related manufacturing method849US 8,753,664 B2Perouse Medical · 2014
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Process for preparing diaminophenothiazinium compounds687US 8,765,942 B2Provence Technologies · 2014
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005